Is there any generic version of Inavolisib currently available?

Inavolisib (Inavolisib), as the latest generation of PI3Kα inhibitors, is currently a new drug within the patent protection period worldwide, so there are no generic versions produced in any country or region. There are no generic drugs on the market, whether in Europe, America, Asia or developing countries. At this stage, all inaliside available through all channels is the original drug. In the overseas open market, the price of its original research is relatively high, usually in the range of hundreds of thousands of yuan per box, and fluctuates due to exchange rates and distribution channels. This is a structural price feature caused by high research and development costs and new drug patent protection. Therefore, when patients inquire about drug purchase channels, they usually pay attention to the price differences in supply chains in different countries, but the overall price is still high.

The high price and lack of generic versions means that it is still regarded as an innovative drug globally, rather than a mature variety that can be widely popularized. Manufacturers will maintain market exclusivity on original new mechanisms during the patent protection period to ensure cost recovery during the drug research and development phase. Usually, whether generic drugs of this type of innovative targeted drugs will appear in the future will have to wait for the patent authorization period to end, and this process often takes several years.

In terms of medical needs, the therapeutic indications of inaliset are mainly concentrated in PIK3CA mutated HR+/HER2- advanced breast cancer patients. Such patients often have received multiple types of treatments, so they have higher requirements for drug safety, tolerability and combination drug strategies. Original drugs have higher guarantees in terms of quality stability and consistency, which is one of the reasons why there are no generic drugs but still maintain clinical demand. As more real-world data and long-term follow-up results are released, future medical insurance policies, price negotiations, and the competitive landscape of generic drugs may change. However, at the current time point, the global supply stage of original drugs is exclusive.

Reference materials: https://www.itovebi-hcp.com/